BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 12828834)

  • 21. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 22. Fasting and insulin glargine in individuals with type 1 diabetes.
    Mucha GT; Merkel S; Thomas W; Bantle JP
    Diabetes Care; 2004 May; 27(5):1209-10. PubMed ID: 15111549
    [No Abstract]   [Full Text] [Related]  

  • 23. Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec.
    Takahashi N; Tsujimoto T; Inoue K; Kishimoto M; Kajio H
    J Diabetes Investig; 2016 Sep; 7(5):805-6. PubMed ID: 27586093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Insulins and New Aspects in Insulin Delivery.
    Woo VC
    Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine.
    Davies M; Storms F; Shutler S; Bianchi-Biscay M; Gomis R;
    Diabetes Care; 2005 Jun; 28(6):1282-8. PubMed ID: 15920040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
    Clements JN; Threatt T; Ward E; Shealy KM
    Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.
    Hsia E; Seggelke S; Gibbs J; Hawkins RM; Cohlmia E; Rasouli N; Wang C; Kam I; Draznin B
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3132-7. PubMed ID: 22685233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixing insulin lispro and ultralente insulin.
    Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
    Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
    [No Abstract]   [Full Text] [Related]  

  • 30. [Researchers illuminate diabetes therapy].
    Pflege Z; 2014 Feb; 67(2):126. PubMed ID: 24730335
    [No Abstract]   [Full Text] [Related]  

  • 31. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain.
    Schreiber SA; Russmann A
    Exp Clin Endocrinol Diabetes; 2006 Jan; 114(1):41-2. PubMed ID: 16450317
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus.
    Ristic S; Bates PC
    Diabetes Technol Ther; 2003; 5(1):57-66. PubMed ID: 12725708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.
    Dungan KM; Buse JB; Herman WH; Arakaki RF; Jiang HH; Jacobson JG; Fahrbach JL
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e66-9. PubMed ID: 22421598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin glargine (Lantus).
    Owens DR; Griffiths S
    Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin glargine clinical trials.
    White JR
    Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
    [No Abstract]   [Full Text] [Related]  

  • 36. Initiating basal insulin therapy in patients with type 2 diabetes mellitus.
    Stoneking K
    Am J Health Syst Pharm; 2005 Mar; 62(5):510-8. PubMed ID: 15745915
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.
    Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG
    Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785
    [No Abstract]   [Full Text] [Related]  

  • 38. A pilot study to evaluate the effectiveness of glargine and multiple injections of lispro in patients with type 2 diabetes receiving tube feedings in a cardiovascular intensive care unit.
    Grainger A; Eiden K; Kemper J; Reeds D
    Nutr Clin Pract; 2007 Oct; 22(5):545-52. PubMed ID: 17906278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin glargine dosing before next-day surgery: comparing three strategies.
    Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
    J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical perspectives in type 2 diabetes care: optimizing glycemic control with insulin therapy.
    Diabetes Educ; 2005; Suppl():1-14; quiz 15-6. PubMed ID: 15786628
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.